Navigation Links
Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
Date:8/14/2013

ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three and six months ended June 30, 2013 and provided an operational update.

The Company's development portfolio includes three anti-infective product candidates, two of which are being developed in collaboration with Intrexon Corporation (NYSE: XON), and an oral multiple sclerosis (MS) product candidate in Phase II development. The relapsing-remitting MS clinical trial is expected to be completed in January 2014, with key data to be released shortly thereafter.Conference call scheduled for 4:00pm EDT today. To participate, please call1-800-860-2442 (U.S. toll free), 1-866-605-3852 (Canada), or +1 412-858-4600 (International),fifteen minutes before the start of the call to register. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=95523. "Our lead anti-infective candidate SYN-004 for the prevention of C. difficile (C. diff) infections, is a second generation compound designed to address a broader population than its predecessor, which successfully completed a proof-of-concept Phase II study in Europe," said Jeffrey Riley, Synthetic Biologics' CEO. "Manufacturing of SYN-004 is underway, and with completion of that we will be able to commence toxicology bridging studies, followed by the start of clinical trials in 2014."

"In addition, we are making excellent progress in our collaboration with Intrexon for antibody programs, which currently covers treatment candidates for Pertussis and Acinetobacter infections. We expect to initiate IND-enab
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... Boston, MA (PRWEB) , ... August 27, 2015 , ... ... the United States, ranking iLab Solutions as number 1,361 in growth for the three ... part of the top 0.1% fastest-growing privately held organizations in the country. , ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... Accelerating Your Research with the BD FACSCanto , ... . , Introduction ... Sampler (HTS) provides fully automated and rapid sample acquisition. It is designed to ... 1% or less. The BD HTS adapts to the BD FACSCanto ...
... Jason S. Wood, Varian, Inc. , ... Cytochrome P450s (CYPs) are heme-containing enzymes responsible for ... are part of the Phase I (oxidative) metabolism within the body, ... easy elimination of the drug or further conjugation by Phase II ...
... D. Garteiz, R. Morrow, and B. Alexander, TexMS Analytical Services, Houston, TX ... Inc., Walnut Creek, CA , ... that make up the pigments in fruits, vegetables, and herbs. There have ... number of serious illnesses, such as rheumatoid arthritis, cancer, cataracts, anxiety, and ...
Cached Biology Technology:Technical Specifications, Accelerating Your Research with the BD FACSCanto, High Throughput Sampler Option 2Technical Specifications, Accelerating Your Research with the BD FACSCanto, High Throughput Sampler Option 3Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 2Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 3Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System 2Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System 3
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... live longer and experience delays in disease progression when a ... added to treatment with erlotinib, the results of a double-blind ... lung cancer research for the Sarah Cannon Research Institute in ... of the European Society for Medical Oncology (ESMO) in Milan, ...
... pregnancy with twins is about 40%. Women with multiple ... the term of their pregnancy. Joachim W Dudenhausen from ... from Magdeburg University Medical Center, investigate which risks can ... Arztebl Int 2010; 107[38]: 663-8). 14 in 1000 ...
... professor has received a U.S. Department of Agriculture grant ... adolescence. Rusty Tchernis, an associate professor of ... received a $225,000 grant to study the "Dynamics of ... University. Tchernis said, the research will explore whether ...
Cached Biology News:New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... the Flp-In System creates isogenic cell ... levels of the protein of interest. ... Figure 3 (click link below). In ... chloramphenicol-acetyl transferase (CAT) was subcloned into ...
... solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, p-xylene, dimethyl sulfoxide, freon ... * Range: 12-position switchable: ... ... ...
Biology Products: